UBS Group AG Raises Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) (2024)

UBS Group AG increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 121.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 274,524 shares of the company's stock after buying an additional 150,517 shares during the quarter. UBS Group AG owned about 0.31% of Intellia Therapeutics worth $8,370,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its stake in Intellia Therapeutics by 2.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company's stock worth $21,350,000 after buying an additional 18,987 shares during the period. Barclays PLC raised its stake in shares of Intellia Therapeutics by 15.0% in the third quarter. Barclays PLC now owns 256,626 shares of the company's stock worth $8,115,000 after purchasing an additional 33,558 shares during the last quarter. ARK Investment Management LLC raised its stake in shares of Intellia Therapeutics by 14.7% in the fourth quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company's stock worth $347,966,000 after purchasing an additional 1,463,820 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Intellia Therapeutics by 5.9% in the third quarter. American Century Companies Inc. now owns 267,213 shares of the company's stock worth $8,449,000 after purchasing an additional 14,863 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its stake in shares of Intellia Therapeutics by 13.3% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 36,225 shares of the company's stock worth $1,104,000 after purchasing an additional 4,255 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $23.52 on Tuesday. The stock has a fifty day simple moving average of $24.03 and a two-hundred day simple moving average of $27.06. Intellia Therapeutics, Inc. has a 1-year low of $19.37 and a 1-year high of $47.48.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($1.06) EPS for the quarter, topping analysts' consensus estimates of ($1.35) by $0.29. Intellia Therapeutics had a negative return on equity of 45.35% and a negative net margin of 893.34%. The firm had revenue of $28.94 million during the quarter, compared to analyst estimates of $15.60 million. Equities research analysts expect that Intellia Therapeutics, Inc. will post -5.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

NTLA has been the subject of several analyst reports. The Goldman Sachs Group downgraded Intellia Therapeutics from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $136.00 to $32.00 in a research note on Friday, February 23rd. StockNews.com raised Intellia Therapeutics to a "sell" rating in a research note on Friday, May 10th. Citigroup reduced their target price on Intellia Therapeutics from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Friday, May 10th. BMO Capital Markets upped their target price on Intellia Therapeutics from $62.00 to $70.00 and gave the company an "outperform" rating in a report on Friday, May 10th. Finally, Wolfe Research began coverage on Intellia Therapeutics in a report on Thursday, February 15th. They issued a "peer perform" rating for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $66.77.

Check Out Our Latest Report on Intellia Therapeutics

Intellia Therapeutics Profile

(Free Report)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

Further Reading

• Five stocks we like better than Intellia Therapeutics
• What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
• Why Smartsheet Stock is an Undervalued Gem of an Investment
• Retail Stocks Investing, Explained
• The Most Upgraded Stocks After the Q1 Earnings Season

Should you invest $1,000 in Intellia Therapeutics right now?

Before you consider Intellia Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.

While Intellia Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here